How does cisplatin boost checkpoint therapy?
Cisplatin-triggered tumor ferroptosis polarized N1 neutrophils and remodeled cold NSCLC tumors toward hotter T-cell/Th1 states, synergizing with ferroptosis activators in EGFR-mutant settings.
Source
Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils
Study at a glance
- Design
- Animal / in-vitro — Tumor-cell ferroptosis, N1 neutrophil polarization, and ICI efficacy after cisplatin
- N
- Preclinical tumor models and cell experiments
- Population
- Tumor cells and mouse tumor-microenvironment models
- Outcome
- ICI efficacy after cisplatin-induced ferroptosis and neutrophil polarization
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
How does cisplatin boost checkpoint therapy?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
Authors report cisplatin→ferroptosis→N1 neutrophils remodeling cold to hot tumors.
In this study, we found that cisplatin induced ferroptosis of tumor cells, followed by N1 neutrophil polarization in the tumor microenvironment, which in turn remodeled the “cold” tumor to a “hot” one through enhancing T-cell infiltration and Th1 differentiation
Clinical chemo-IO context?
first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) with negative driver gene mutations
What they did
Studied cisplatin effects on ferroptosis and neutrophil polarization in NSCLC models (including A549/LLC systems), assessed T-cell infiltration/Th1 differentiation, and tested ferroptosis-activator combinations aimed at EGFR-mutant immunotherapy resistance.
What they found
Cisplatin induced tumor-cell ferroptosis then N1 neutrophil polarization that helped convert “cold” to “hot” tumors via T-cell infiltration and Th1 differentiation; ferroptosis activation synergized with chemoimmunotherapy in EGFR-mutant NSCLC models.
The limits
What it doesn't show
Mouse/cell mechanisms may not fully predict human EGFR-mutant responses; clinical dosing/schedule optimization was not a randomized patient trial here.
Key terms
- Ferroptosis
- Iron-dependent regulated cell death exploited here by cisplatin.
- N1 neutrophils
- Anti-tumor polarized neutrophils in the tumor microenvironment.
- Cold vs hot tumor
- Poor vs rich T-cell inflamed immune microenvironment.
- ICI
- Immune checkpoint inhibitor therapy.
- EGFR-mutant NSCLC
- Lung cancers with EGFR drivers often less ICI-responsive.
Flashcards
0 of 8 answers reviewed
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
Cisplatin was proposed to induce:
Common questions
Key cisplatin immune sequence?
Ferroptosis → N1 neutrophils → hotter T-cell/Th1 milieu.
Cold→hot remodeling via?
Enhanced T-cell infiltration and Th1 differentiation.
Combo idea for EGFR-mutant disease?
Add a ferroptosis activator to chemoimmunotherapy.
Example cell models?
A549 and LLC among others.